A Randomized, Open-label, Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician?s Choice in Patients With Hormone Receptor-Positive HR+/Human Epidermal Growth Factor Receptor 2 Negative HER2? HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH?] Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05840211

Study #:
STUDY00150129

Start Date:
Aug 30, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05840211

View Complete Trial Details & Eligibility at ClinicalTrials.gov